TK1 and neoplasm: Analysis of Ki-67 staining (Fig. 5B) demonstrated that proliferation had halted by day 3 after the start of cetuximab monotherapy in the drug-sensitive model, with a concomitant reduction in TK1 and tumor thymidine (Figs. 6 and 7A).